Neoadjuvant therapy can reduce tumor burden, increase R0 rate and improve survival rate.In recent years, with the emergence of PD-L1 inhibitors, the strategy of chemotherapy combined with PD-L1 inhibitors has changed the treatment prospects of non-small cell lung cancer [6–8]. The gene discussed is CD274; the disease is neoplasm.